Recombinant human VG5Q   

AGGF 1; AGGF-1; Angiogenic factor VG5Q; Angiogenic factor with G patch and FHA domains 1; FLJ10283; G patch domain containing protein 7; GPATC 7; GPATC7; GPATCH 7; GPATCH7; HSU84971; HUS84971; hVG5Q; Vasculogenesis gene on 5q; Vasculogenesis gene on 5q protein; AGGF1_HUMAN.    

濃度：1mg/ ml

來源：Recombinant Human

純度：≥95% SDS-PAGE

表達系統(tǒng)：Escherichia coli

標(biāo)簽：His tag

蛋白長度：Full length protein

內(nèi)毒素水平：<1.000 Eu/µg

純化方法：HPLC

應(yīng)用：SDS-PAGE，Western blot，ELISA

Biological activity,immunology research

保存：-20℃

保質(zhì)期：1年

Angiogenic factors are critical to the initiation of angiogenesis and maintenance of the vascular network. VG5Q protein acts as a potent angiogenic factor in promoting angiogenesis, and suppression of VG5Q expression inhibits vessel formation. VG5Q shows strong expression in blood vessels and is secreted as vessel formation is initiated. VG5Q can bind to endothelial cells and promote cell proliferation, suggesting that it may act in an autocrine fashion. It also interacts with another secreted angiogenic factor, TWEAK (also known as TNFSF12). VG5Q is defective in patients with the vascular disease Klippel-Trenaunay syndrome (KTS).

Recombinant human VG5Q   

AGGF 1; AGGF-1; Angiogenic factor VG5Q; Angiogenic factor with G patch and FHA domains 1; FLJ10283; G patch domain containing protein 7; GPATC 7; GPATC7; GPATCH 7; GPATCH7; HSU84971; HUS84971; hVG5Q; Vasculogenesis gene on 5q; Vasculogenesis gene on 5q protein; AGGF1_HUMAN.    

濃度：1mg/ ml

來源：Recombinant Human

純度：≥95% SDS-PAGE

表達系統(tǒng)：Escherichia coli

標(biāo)簽：His tag

蛋白長度：Full length protein

內(nèi)毒素水平：<1.000 Eu/µg

純化方法：HPLC

應(yīng)用：SDS-PAGE，Western blot，ELISA

Biological activity,immunology research

保存：-20℃

保質(zhì)期：1年

Angiogenic factors are critical to the initiation of angiogenesis and maintenance of the vascular network. VG5Q protein acts as a potent angiogenic factor in promoting angiogenesis, and suppression of VG5Q expression inhibits vessel formation. VG5Q shows strong expression in blood vessels and is secreted as vessel formation is initiated. VG5Q can bind to endothelial cells and promote cell proliferation, suggesting that it may act in an autocrine fashion. It also interacts with another secreted angiogenic factor, TWEAK (also known as TNFSF12). VG5Q is defective in patients with the vascular disease Klippel-Trenaunay syndrome (KTS).